Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion
Study Details
Study Description
Brief Summary
To assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Two recent randomized, controlled trials from China-ATTENTION (Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion) and BAOCHE (Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion) have shown a significantly beneficial effect of endovascular thrombectomy in patients with an acute symptomatic basilar artery occlusion. The DEVT (Direct Endovascular Treatment versus Standard Bridging Therapy for Acute Stroke Patients with Large Vessel Occlusion in The Anterior Circulation) and DIRECT-MT (Direct Intraarterial Thrombectomy in Order to Revascularize Acute Ischemic Stroke Patients with Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals Trial) trials showed that endovascular thrombectomy alone is not inferior to intravenous alteplase bridging with endovascular treatment in terms of achieving 90-day functional independence for stroke patients with large vessel occlusion. However, it is unclear whether endovascular thrombectomy alone is noninferior to intravenous thrombolysis bridging with endovascular thrombectomy for achieving functional independence at 90 days among patients with acute basilar artery occlusion. Therefore, additional studies are needed to explore the potential benefit of endovascular thrombectomy alone in these patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Endovascular thrombectomy alone Patients will receive endovascular thrombectomy without intravenous thrombolysis. |
Procedure: Endovascular thrombectomy
Endovascular thrombectomy
|
| Active Comparator: Intravenous thrombolysis plus endovascular thrombectomy Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy. |
Drug: Intravenous thrombolysis
Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
Other Names:
Procedure: Endovascular thrombectomy
Endovascular thrombectomy
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days) [90 (± 14 days) after procedure]
Functional independence outcomes
Secondary Outcome Measures
- Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days) [90 (± 14 days) after procedure]
Evaluate functional outcome
- Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days) [90 (± 14 days) after procedure]
Evaluate functional outcome
- Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days) [90 (± 14 days) after procedure]
Evaluate functional outcome
- Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days) [90 (± 14 days) after procedure]
Evaluate disability level
- Score on the National Institute of Health Stroke Scale (NIHSS) at 24 hours [24 hours after procedure]
The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit.
- Score on the NIHSS at 5-7 days or discharge [5-7 days or discharge after procedure]
The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit.
- Score on the EuroQoL 5-dimensions 5-level (EQ5D-5L) at 90 days (±14 days) [90 (± 14 days) after procedure]
Health-related quality of life, assessed with EQ-5D-5L
- level of activities of daily living (Barthel index, BI) at 90 days (±14 days) [90 (± 14 days) after procedure]
Level of activities of daily living
- Successful reperfusion (Extended thrombolysis in cerebral infarction [eTICI] score 2b50-3) on digital substraction angiography (DSA) prior to thrombectomy [within 5 minutes at angiography]
Evaluate effect of intravenous thrombolysis on reperfusion
- Successful reperfusion on final angiography of thrombectomy [Within 5 minutes at final angiography of thrombectomy]
Evaluate effect of thrombectomy on reperfusion
- Successful recanalization on CT or MR angiography within 72 hours [Within 72 hours after procedure]
Evaluate vascular patency after treatment
- Infarct volume (Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score, PC-ASPECTS) evaluated on CT or MRI within 72 hours [Within 72 hours after procedure]
PC-ASPECTS=10 indicates a normal scan, PC-ASPECTS=0 indicates early ischemic changes or hypoattenuation in all above territories. 1 or 2 points each are subtracted for early ischemic changes or hypoattenuation in: left or right thalamus, cerebellum or posterior cerebral artery territory, respectively (1 point); any part of midbrain or pons (2 points)
Other Outcome Measures
- Symptomatic intracerebral hemorrhage (sICH) within 72 hours [Within 72 hours after procedure]
SICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death
- Any intracerebral hemorrhage within 72 hours [Within 72 hours after procedure]
Evaluate intracerebral hemorrhage
- Overall mortality at 7 (± 2 days) and 90 (± 14 days) [7 (± 2 days) and 90 (± 14 days) after procedure]
Evaluate death rate
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;
-
Time from stroke onset to randomization within 4.5 hours of estimated time of basilar artery occlusion;
-
Patient's age ≥ 18 years;
-
Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA) or MR Angiography (MRA). In case of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;
-
Patients presenting with acute ischemic stroke eligible to receive both endovascular thrombectomy and intravenous thrombolysis using standard criteria;
-
Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 10;
-
The patient or patient's legal representative signs the informed consent form.
Exclusion Criteria:
-
CT or MR evidence of intracerebral hemorrhage (the presence of < 10 microbleeds is allowed);
-
Pre-stroke modified Rankin scale (mRS) score ≥ 2;
-
Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) <5;
-
Pregnant or lactating women;
-
Allergy to contrast agent or nitinol alloy;
-
Life expectancy<1 year;
-
CTA/MRA show vascular tortuosity, anatomical variation or artery dissection, which would make it difficult to perform endovascular treatment;
-
Participating in other clinical trials;
-
Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, which can not be controlled by antihypertensive drugs;
-
Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; oral anticoagulant with international normalized ratio (INR) > 1.7; or novel oral anticoagulant within prior 48 hours;
-
Blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L), platelet< 100*109/L;
-
Renal insufficiency defined as serum creatinine >2.0 mg/dl (or 176.8 μ mol/l), glomerular filtration rate <30 mL/min, need for hemodialysis or peritoneal dialysis;
-
Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc);
-
The patient has acute ischemic cerebral infarction within 3 months from randomization;
-
The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis;
-
The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition;
-
CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle;
-
Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination;
-
CTA/MRA show both anterior and posterior circulation large vessel occlusion;
-
Patients with intracranial tumors (except small meningiomas);
-
Patients who received intravenous thrombolytics treatment before the randomization.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- The First Affiliated Hospital of University of Science and Technology of China
Investigators
- Study Chair: Wei Hu, MD, The First Affiliated Hospital of University of Science and Technology of China
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ATTENTION-IV Early